Gear Patrol Names Mikra’s CELLF as One of 12 Most Interesting Nutrition Products and Supplements of 2022
CELLF, Initial Product from Lifeist’s Mikra Nutraceutical Subsidiary, Honored by Popular and Award-Winning Publication
TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced that its wellness and nutraceutical subsidiary, Mikra, Cellular Sciences Inc. (“Mikra”), had its first product, CELLF, honored as one of the “most interesting nutrition products and supplements of 2022” in a recent article on GearPatrol.com.
CELLF is a novel cellular therapeutic compound that targets systemic fatigue, particularly in individuals over the age of 30. Gear Patrol noted that “the effects (of CELLF) can be recognized rather quickly over routine use,” and added “If you’re looking for an innovative way to repair your cells for the sake of improved cognitive function, boosted energy, better sleep and more, this is the nutritional add-on for you.”
“It’s an honor for CELLF to be recognized by Gear Patrol, one of the definitive buying guides for today’s generation of consumers, and which should help create even greater awareness for Mikra and our expanding offering of nutraceutical products,” commented Faraaz Jamal, CEO of Mikra and COO of Lifeist. “We recently introduced our second major product, RESCUE, a 100% naturally derived and rapid-acting digestive aid, and we are advancing a new and improved formulation of CELLF to bolster already encouraging market reception. Our team is heavily immersed in research and development to expand our product roadmap in meaningful and unique ways, and as we look into 2023, we expect to not only further add to our portfolio but also broaden retail and online distribution.”
Added Meni Morim, Lifeist CEO, "Product innovation and brand strength are two key metrics for Mikra as we look for it to become another growth engine for Lifeist this year, culminating in our evolution to a wellness-first company. Mikra's continued progress and emerging opportunities gives me confidence that this transition is well underway."
CELLF is available for purchase at www.wearemikra.com.
About Lifeist Wellness Inc.
Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include: CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards including for CannMart Labs, a BHO extraction facility producing high margin cannabis 2.0 products; Australian Vapes, one of Australia’s largest online retailers of vaporizers and accessories; and Mikra, a biosciences and consumer wellness company developing and selling innovative therapies for cellular health.
Information on Lifeist and its businesses can be accessed through the links below:
www.lifeist.com
https://cannmart.com
https://www.roilty.co
www.australianvaporizers.com.au
www.wearemikra.com
Contacts
Meni Morim, Lifeist Wellness Inc., CEO
Matt Chesler, CFA, FNK IR, Investor Relations
Ph: 647-362-0390
Email: ir@lifeist.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.
Forward Looking Information
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.
The forward-looking information contained herein, including, without limitation, statements related to the anticipated launch of additional products and the broadening of retail and online distribution channels for Mikra’s products during 2023, are made as of the date of this news release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, expectations that Mikra’s additional cellular health products to be developed by the Company will be developed and sold as anticipated and in a timely manner and gain market acceptance along with the expansion of the market for nutraceutical products, its expectation that the nutraceutical market will continue to develop as currently anticipated, the nutraceutical market will continue to be a multi-billion dollar high-margin market, the introduction of new products, brands and distribution channels will generate additional awareness of Mikra’s existing and future products and increase revenue. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: the failure to develop and launch for sale additional products in 2023 and the inability to increase distribution through new retail and online channels as anticipated and in a timely manner, the Company’s inability to continue to develop Mikra’s business as a whole, unanticipated changes to current regulations that would adversely impact Mikra’s business, unforeseen developments that would delay Mikra’s ability to develop and sell any other nutraceutical products, the risk that the expected demand for nutraceutical products in general and those of Mikra in particular, including consumer uptake, does not develop as anticipated and risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom. Additional risk factors can also be found in the Company’s current MD&A which has been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Source: Lifeist Wellness Inc.
